Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TNFRSF8 expression
i
Other names:
TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
943
Related biomarkers:
Expression
Others
‹
›
Associations
(12)
News
Trials
Search handles
@AaronGoodman33
@graham74GC
@hematologo
Search handles
@AaronGoodman33
@graham74GC
@hematologo
Filter by
Latest
11ms
#17ICML Brentuximab in DLBCL. The best response is combining BV plus lenalidomide (31% CRR in R/R DLBCL. Remember 1/3 of patients will express CD30+. @GuiperiniMD @Denicasuri @GELL01433166 (@hematologo)
11 months ago
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
lenalidomide • Adcetris (brentuximab vedotin)
over1year
what would the ideal treatment be for a primary refractory DLBCl with 70% of cells expressing CD30 apart from the B cell markers. Progressed on R-CVP. 77 year old. PS-1. anyone would try brentuximab in this setting off label? @BijoyTelivala, @Prasshmehta @AaronGoodman33 (@drnitinyashas)
over 1 year ago
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
Rituxan (rituximab) • Adcetris (brentuximab vedotin)
over1year
Dr Savoldo - tour de force of CAR-T in Hodgkin. - CD30 targeting producing responses, some durable. - Low MTV assoc with response. - Mouse models suggest co-expn CCR4 may improve homing. - Studies of CD30 CAR / CCR4 expressing cells ongoing. #ISHL12 #ISHL22 (@graham74GC)
over 1 year ago
Preclinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR4 (C-C Motif Chemokine Receptor 4)
|
TNFRSF8 expression
over2years
Ph2 Open-Label #clinicaltrial open @RutgersCancer: Brentuximab Vedotin in Front-Line Therapy of Hodgkin #Lymphoma & CD30-Expressing Peripheral T-Cell Lymphoma in Older Patients/ Patients w/ Significant Comorbidities Ineligible for Standard Chemo @DrAEvens https://t.co/uNDgN0Yjbf (@RutgersCancer)
over 2 years ago
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
over2years
#ASH21 CD30-Directed CAR-T Cells Co-Expressing CCR4 in R/R cHL & CD30+ Cutaneous TCL. ✔️n=13 (6 DL1, 3 DL2, 3 DL3, 1 DL4) ✔️Median 5.5 LOT ✔️6/8 HL CR ✔️No dose limiting toxicities ✔️Responses seen at the lowest dose level @NatalieGroverMD @CARTTherapy (@uroosaibrahim)
over 2 years ago
CAR T-Cell Therapy
|
CCR4 (C-C Motif Chemokine Receptor 4)
|
TNFRSF8 expression
over2years
Lymphoma Question! Newly diagnosed stage IV angioimmunoblastic T-cell lymphoma in a fit 60 year old patient. IPI = 4 CD30 expression on neoplastic cells = 5%. NGS with TET2 mutations You recommend... (@AaronGoodman33)
over 2 years ago
Clinical • Next-generation sequencing
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • TET2 (Tet Methylcytosine Dioxygenase 2)
|
TET2 mutation • TNFRSF8 expression
over2years
Ph2 Open-Label #clinicaltrial open @RutgersCancer: Brentuximab Vedotin in Front-Line Therapy of Hodgkin #Lymphoma & CD30-Expressing Peripheral T-Cell Lymphoma in Older Pts or Pts w/ Significant Comorbidities Ineligible for Standard Chemo https://t.co/8b3Xew0H54 @DrAEvens (@RutgersCancer)
over 2 years ago
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
over2years
Board Review A fit 65 yo with stage IV angioimmunoblastic T cell lymphoma is in CR after 6 cycles of CHOP. CD30 is expressed in 20% of cells. You recommend….Best answer of 4. (@AaronGoodman33)
over 2 years ago
Review
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
over2years
Ph2 Open-Label #clinicaltrial open @RutgersCancer: Brentuximab Vedotin in Front-Line Therapy of Hodgkin #Lymphoma & CD30-Expressing Peripheral T-Cell Lymphoma in Older Pts or Pts w/ Significant Comorbidities Ineligible for Standard Chemo https://t.co/uNDgN0Yjbf @DrAEvens (@RutgersCancer)
over 2 years ago
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
over2years
CD30 expression in lymphoma 100% of time Hodgkin lymphoma Systemic anaplastic large cell lymphoma (Both ALK-/+) Primary cutaneous ALCL Lymphomatoid papulosis Sometimes DLBCL PTCL, NOS Angioimmunoblastic Mycosis fungoides (more often with large cell transformation) (@AaronGoodman33)
over 2 years ago
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
over2years
Heme and dermatology aficionados don’t disappoint me. 50 yo with new diagnosis mycosis fungoides with 25% body surface area involvement with patch/plaque stage disease. PET and blood negative. Biopsy with atypical CD7- T cells that strongly express CD30. Best treatment rec? (@AaronGoodman33)
over 2 years ago
TNFRSF8 (TNF Receptor Superfamily Member 8) • CD7 (CD7 Molecule)
|
TNFRSF8 expression
3years
Interesting observation but hard to interpret the data. Both EBV infection and SARS-Cov2 can cause mild PET+ adenopathy. Also, EBV infection can induce CD30 expression that could mimic Hodgkin lymphoma. More data will be needed (@DrAnasYounes)
3 years ago
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login